Evaxion refocuses on cancer vaccines
Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.
The Hørsholm-based company says the move builds on clinical validation of its platform through EVX-01, a personalized cancer vaccine. It also sees a wider opportunity in off-the-shelf cancer vaccines across several indications, using a broader range of new antigens, such as endogenous retroviruses.
Evaxion will now focus on moving its off-the-shelf vaccines EVX-04 and EVX-05 toward clinical development, and on expanding EVX-01 into more indications through partnerships. It will also keep mining the “dark genome,” the large share of the genome that does not code for proteins, for new vaccine targets. The company plans to advance its preclinical infectious disease assets through partnerships and to finish validating its autoimmune concepts for future partners.
“We are refocusing our strategy on the unique capabilities of AI-Immunology in discovery and design of novel cancer vaccines. Our platform has recently been further validated by stronger clinical and translational data from the Phase II trial with EVX-01 in advanced melanoma, at a time when the entire landscape around personalized cancer vaccines has changed for the better,” says Helen Tayton-Martin, CEO of Evaxion.
Published: November 19, 2026
